Needham & Company Starts Cytokinetics (CYTK) at Buy; Well Capitalized to Execute
Tweet Send to a Friend
Needham & Company initiates coverage on Cytokinetics (NASDAQ: CYTK) with a Buy. PT $2.50.
Analyst, Chad Messer, said, "Cytokinetics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Chad Messer, said, "Cytokinetics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
